Mercaptopurine (6-MP)

Catalog No.S1305

Mercaptopurine (6-MP) Chemical Structure

Molecular Weight(MW): 152.18

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Size Price Stock Quantity  
In DMSO USD 100 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells NG\2ZYpHfW6ldHnvckBie3OjeR?= MlfMTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH;uJI12dHSrZIL1[{1z\XOrc4ThcpQhVDF{MUCgcIV2c2WvaXGgZ4VtdHNuIFnDOVA:OC5yMkSg{txO MnvUNVkxPjFyNx?=
MT4 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 MkL2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVESgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNUDPxE1? NYXsVGJoOTd{NUS2Olk>
human CCRF-CEM cells MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 NV3EfXBvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MTFOwG0> NITjWHMyPzJ3NE[2PS=>
human CCRF-SB cells NWTXTno5WHKxbHnm[ZJifGmxbjDhd5NigQ>? NFHpOZpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuW0JiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN NWjh[ItHOTd{NUS2Olk>
human SK-MEL-28 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV3FUE0zQCClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OTVizszN NHG2eY4yPzJ3NE[2PS=>
human MCF7 cells MoqzVJJwdGmoZYLheIlwdiCjc4PhfS=> NX;CdIZkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0{KM7:TR?= MUSxO|I2PDZ4OR?=
human HepG2 cells NVzBPWIxWHKxbHnm[ZJifGmxbjDhd5NigQ>? NX;3OGNkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:QCEQvF2= NFH0e4wyPzJ3NE[2PS=>
human DU145 cells M4\nTHBzd2yrZnXyZZRqd25iYYPzZZk> NITBPXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0zKM7:TR?= MUixO|I2PDZ4OR?=
mouse J774.A1 cells NIPz[W5Rem:uaX\ldoF1cW:wIHHzd4F6 NVTJOmdCOyCmYYnz M2DPSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViSke3OE5COSClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGOxbo\ldpNqd25iYYPzZZktKEmFNUC9NE4xODNizszN M{\NclE3PjR|MESw
HEK293 cells MVjQdo9tcW[ncnH0bY9vKGG|c3H5 Mle5N{Bl[Xm| MkjLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDISWszQTNiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODB5IN88US=> NY\kRmRbOTZ4NEOwOFA>
mouse J774 cells M4nBNHBzd2yrZnXyZZRqd25iYYPzZZk> Mmq4O|IhcA>? Mnz3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCMN{e0JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUJI1mfGixZDygTWM2OD1yLkCwN{DPxE1? NHzuO2MyODd3N{ewPC=>
human PBMC M3XoV2Z2dmO2aX;uJIF{e2G7 NWLo[oV2PCCmYYnz MXvJcohq[mm2aX;uJI9nKFRiY3XscEBucXSxZ3XuMYlv\HWlZXSgZoxie3SxZ3Xu[ZNqeyCrbjDoeY1idiCSQl3DJIFnfGW{IESg[IF6eyxiSVO1NF0xNjF2OUWg{txO NEXvcWYyQDR4N{CwOy=>
HeLa cells MnH5R5l1d3SxeHnjbZR6KGG|c3H5 NG\PflM1QCCq NHG3T2lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG2IHzh[{BxcGG|ZTDv[kBoem:5dHigZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lkmg{txO NEPRNmoyQTdzMUm4Oy=>
A549 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= MVq0PEBp NWC5em9LS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjdDDsZYcheGijc3Wgc4Yh\3Kxd4ToJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NEeg{txO M1S1XVE6PzFzOUi3
MCF7 cells Mmi1R5l1d3SxeHnjbZR6KGG|c3H5 M2PjcVQ5KGh? NXPEcpNsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjdDDsZYcheGijc3Wgc4Yh\3Kxd4ToJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT60JO69VQ>? NFvG[44yQTdzMUm4Oy=>
MT4 cells MW\DfZRwfG:6aXPpeJkh[XO|YYm= NIK2fWc6PiCq NIK4VZJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXDRiY3XscJMhcW6oZXP0[YQhf2m2aDDIWGxXNTFiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NF0xNjFizszN NW[3TI9EOjF5NEGxN|A>
CCRF-CEM cells NVnrfIxyWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVjZcWxJQTZiaB?= M3;rfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2xJO69VQ>? NFr6SWszOTd2MUGzNC=>
WIL2-NS cells NUTT[YZNWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFXINWw6PiCq MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLTEKtUnMh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OD1|IN88US=> MXOyNVc1OTF|MB?=
CCRF-SB cells MmDwVJJwdGmoZYLheIlwdiCjc4PhfS=> M2DWbVk3KGh? MoTlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMXNDKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MT6xJO69VQ>? NVXOW2hLOjF5NEGxN|A>
human DU145 cells MWjQdo9tcW[ncnH0bY9vKGG|c3H5 M3q4NFk3KGh? MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OiEQvF2= M4LHTFIyPzRzMUOw
human HepG2 cells M4O4cHBzd2yrZnXyZZRqd25iYYPzZZk> NWHsV2VFQTZiaB?= MlG5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDDR|UxRThizszN MljPNlE4PDFzM{C=
MCF7 cells NVX2cWh5WHKxbHnm[ZJifGmxbjDhd5NigQ>? M1raelk3KGh? NF[4VJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OD1|LkKg{txO Ml\3NlE4PDFzM{C=
SK-MEL-28 cells NH\IcVVRem:uaX\ldoF1cW:wIHHzd4F6 NGTlW3I6PiCq M1;S[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NVUh|ryP NXK1c45uOjF5NEGxN|A>
MCF7 cells NHO1dVhEgXSxdH;4bYNqfHliYYPzZZk> NXTPWFZRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyxiSVO1NF0zNjd7IN88US=> NEfjUGIzOzRzMUmxOS=>
mouse S49 cells MlXoR5l1d3SxeHnjbZR6KGG|c3H5 MWC3NkBp NHPuOGJEgXSxdH;4bYNqfHliYXfhbY5{fCC5aXzkJJR6eGVibX;1d4UhWzR7IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFXDOVA:QCEQvF2= M1LIVlIzOTZ3OB?=
Colo-357 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDc4xwNTN3NzDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF03NjF{IN88US=> M3PLe|IxQTNyMUKz
Aspc-1 cells M1PRe2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBd5BkNTFiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9Nk41PSEQvF2= M3X5fVIxQTNyMUKz
A549 cells MYXDfZRwfG:6aXPpeJkh[XO|YYm= NIX0UFg1QCCq NXLZVmk2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQ4KM7:TR?= MkDqNlI4ODVyMEG=
MCF7 cells MnrvR5l1d3SxeHnjbZR6KGG|c3H5 MVy0PEBp MkD1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOEDPxE1? NIm0OVAzOjdyNUCwNS=>
Patu-02 cells MUnDfZRwfG:6aXPpeJkh[XO|YYm= NG\uWXhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR[XS3LUCyJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTlwNkmg{txO NWPVdIVlOjB7M{CxNlM>
Patu-T cells M2m1WmN6fG:2b4jpZ4l1gSCjc4PhfS=> MoDMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIF1fS2WIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVQvODlizszN NIPJUIUzODl|MEGyNy=>
Patu-S cells NWfqeWtZS3m2b4TvfIlkcXS7IHHzd4F6 M2DXSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBifHVvUzDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF0yOS5yNzFOwG0> MXGyNFk{ODF{Mx?=
T3M4 cells MXHDfZRwfG:6aXPpeJkh[XO|YYm= MkHVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFNOPCClZXzsd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whUUN3ME2yMlY{KM7:TR?= NWLDZY1JOjB7M{CxNlM>
human PANC1 cells M1u0eGN6fG:2b4jpZ4l1gSCjc4PhfS=> NHTuTVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSU6FMTDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF03NjN7IN88US=> MoPXNlA6OzBzMkO=
human DAN-G cells MW\DfZRwfG:6aXPpeJkh[XO|YYm= NWLTR3lGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTEGQLVegZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:PC5yNjFOwG0> NGnnTJEzODl|MEGyNy=>
HeLa cells M2TocGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlvYOFghcA>? M2XHVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlkh|ryP M3zOOVIzPzB3MECx
WEHI164 cells Mn;UVJJwdGmoZYLheIlwdiCjc4PhfS=> MlrzN{Bl[Xm| MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFeHSFmxOlQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBkd264ZYLzbY9vKGG|c3H5MEBKSzVyPUCuNFE2KM7:TR?= M4ToWVE3PjR|MESw
WIL-2NS cells MYDQdo9tcW[ncnH0bY9vKGG|c3H5 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLTD2yUnMh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMh|ryP Ml3PNVczPTR4Nkm=
WEHI164 cells M2r0PHBzd2yrZnXyZZRqd25iYYPzZZk> M{jocFczKGh? NYXZZYlDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDXSWhKOTZ2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBk\WyuIHfyc5d1cCCjZoTldkA4OiCqcoOgZpkhVVSWIH3leIhw\CxiSVO1NF0xNjBzNzFOwG0> M{HNOVExPzV5N{C4

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (197.13 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00514982 Withdrawn Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 7, 2007 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02578511 Not yet recruiting Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma in Complete Remission|Mixed Phenotype Acute Leukemia in Complete Remission Ehab L Atallah|Medical College of Wisconsin January 2017 Phase 1
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02828358 Not yet recruiting Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia National Cancer Institute (NCI) December 2016 --
NCT02877303 Recruiting Leukemia|Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center|Amgen November 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID